The Pathobiology of Diabetic Complications
Top Cited Papers
- 1 June 2005
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 54 (6) , 1615-1625
- https://doi.org/10.2337/diabetes.54.6.1615
Abstract
It’s a great honor to join the exceptional club of Banting Award winners, many of whom were my role models and mentors. In addition, giving the Banting Lecture also has a very personal meaning to me, because without Frederick Banting, I would have died from type 1 diabetes when I was 8 years old. However, it was already apparent at the time I was diagnosed that for too many people like me, Banting’s discovery of insulin only allowed them to live just long enough to develop blindness, renal failure, and coronary disease. For example, when I started college, the American Diabetes Association’s Diabetes Textbook had this to say to my parents: “The person with type 1 diabetes can be reassured that it is highly likely that he will live at least into his 30s.” Not surprisingly, my parents did not find this particularly reassuring. At the same time we were reading this in 1967, however, the first basic research discovery about the pathobiology of diabetic complications had just been published in Science the previous year. In my Banting Lecture today, I am thus going to tell you a scientific story that is also profoundly personal. I’ve divided my talk into three parts. The first part is called “pieces of the puzzle,” and in it I describe what was learned about the pathobiology of diabetic complications starting with that 1966 Science paper and continuing through the end of the 1990s. In the second part, I present a unified mechanism that links together all of the seemingly unconnected pieces of the puzzle. Finally, in the third part, I focus on three examples of novel therapeutic approaches for the prevention and treatment of diabetic complications, which are all based on the new paradigm of a unifying mechanism for the pathogenesis of diabetic complications. …This publication has 61 references indexed in Scilit:
- Matrix protein glycation impairs agonist‐induced intracellular Ca2+ signaling in endothelial cellsJournal of Cellular Physiology, 2002
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells.Journal of Clinical Investigation, 1998
- Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats.Journal of Clinical Investigation, 1997
- Glucose Metabolism to Glucosamine Is Necessary for Glucose Stimulation of Transforming Growth Factor-α Gene TranscriptionJournal of Biological Chemistry, 1996
- Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β InhibitorScience, 1996
- Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.Journal of Clinical Investigation, 1995
- Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins.Journal of Clinical Investigation, 1992
- Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy.The Journal of Experimental Medicine, 1991
- Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue RemodelingScience, 1988